Arcutis’ Zoryve Foam Is Now Available for Seb Derm Treatment in the U.S.
Arcutis Biotherapeutics, Inc.’s ZORYVE topical foam, 0.3%, is now officially available for the treatment of seborrheic dermatitis. The U.S. Food and Drug Administration (FDA) approved ZORYVE foam for the treatment of seborrheic dermatitis in individuals 9 years of age and older on December 15, 2023. Roflumilast foam (Zoryve, Arcutis) will be available via wholesaler and pharmacy […]